帕博利珠单抗对比IFNα2b或伊匹木单抗在高危黑色素瘤切除术后的辅助治疗
这项随机III期试验比较了高危黑色素瘤切除术后辅助帕博利珠单抗1年(647例)与IFNα-2b 1年或伊匹木单抗最长3年(654例)的疗效。中位随访47.5个月时,帕博利珠单抗较既往标准辅助免疫治疗显著延长无复发生存期(HR 0.77;99.62%CI 0.59-0.99;P=0.002),但总生存无统计学显著差异(HR 0.82;96.3%CI 0.61-1.09;P=0.15)。
要点
- 帕博利珠单抗较IFNα-2b或伊匹木单抗显著改善无复发生存期(HR 0.77;99.62%CI 0.59-0.99;P=0.002)。
- 总生存无统计学显著差异(HR 0.82;96.3%CI 0.61-1.09;P=0.15)。
- 3-5级治疗相关不良事件发生率:帕博利珠单抗19.5%,IFNα-2b 71.2%,伊匹木单抗49.2%。
核心结论
- 在高危黑色素瘤切除术后患者中,辅助帕博利珠单抗较既往标准辅助免疫治疗显著改善无复发生存期,但未显著改善总生存。
研究设计与样本
- 随机III期试验,比较辅助帕博利珠单抗1年(647例)与IFNα-2b 1年或伊匹木单抗最长3年(654例)在高危黑色素瘤切除术后的疗效。
主要发现
- 中位随访47.5个月时,帕博利珠单抗较既往标准辅助免疫治疗显著延长无复发生存期(HR 0.77;99.62%CI 0.59-0.99;P=0.002)。
- 全部患者中总生存无统计学显著差异(HR 0.82;96.3%CI 0.61-1.09;P=0.15)。
- 3-5级治疗相关不良事件发生率:帕博利珠单抗19.5%,IFNα-2b 71.2%,伊匹木单抗49.2%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We conducted a randomized phase III trial to evaluate whether adjuvant pembrolizumab for one year (647 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison with high-dose IFNα-2b for one year or ipilimumab for up to three years (654 patients), the approved standard-of-care adjuvant immunotherapies at the time of enrollment for patients with high-risk resected melanoma. At a median follow-up of 47.5 months, pembrolizumab was associated with significantly longer RFS than prior standard-of-care adjuvant immunotherapies [HR, 0.77; 99.62% confidence interval (CI), 0.59-0.99; P = 0.002]. There was no statistically significant association with OS among all patients (HR, 0.82; 96.3% CI, 0.61-1.09; P = 0.15). Proportions of treatment-related adverse events of grades 3 to 5 were 19.5% with pembrolizumab, 71.2% with IFNα-2b, and 49.2% with ipilimumab. Therefore, adjuvant pembrolizumab significantly improved RFS but not OS compared with the prior standard-of-care immunotherapies for patients with high-risk resected melanoma. SIGNIFICANCE: Adjuvant PD-1 blockade therapy decreases the rates of recurrence, but not survival, in patients with surgically resectable melanoma, substituting the prior standard-of-care immunotherapies for this cancer. See related commentary by Smithy and Shoushtari, p. 599. This article is highlighted in the In This Issue feature, p. 587.
引用
- Grossmann KF, Othus M, Patel SP, et al. Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discov. 2022. PMID: 34764195. doi:10.1158/2159-8290.CD-21-1141
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。